Drug-Drug Interactions in HIV/HCV Coinfection

Experts discuss the management of drug-drug interactions in patients receiving treatment for HIV and HCV coinfection.

HCV Racial Disparities and Treatment Outcomes

Racial disparities in HCV treatment outcomes can be partially explained by the differences in underlying immune/genetic characteristics of patients.

Preventing HCV With Needle/Syringe Programs

Needle/syringe programs (NSPs) have proven to be effective and moderately effective in preventing transmission of HCV infection and minimizing drug-related harms among people who inject ...

Short-Duration Treatment Regimens for HCV

The high cost of DAA-based regimens remains an ethical issue and an obstacle to treatment accessibility. Shorter treatment regimens may offer substantial cost savings, improved ...

Treatment Challenges for Genotype 3 HCV

Data have shown patients with genotype 3 HCV have faster progression of fibrosis and higher rates of cirrhosis, severe steatosis, and hepatocellular carcinoma.

Hepatocellular Carcinoma: Treatment Challenges

Despite continual efforts aimed at finding new treatment options, HCC still has a very low 5-year survival rate, less than 20%, as many patients are ...

Hepatitis B: Current State of Affairs

One of the main challenges in managing and controlling hepatitis B infection today is identifying people who are infected and ensuring that they have access ...

Latest News

Two Hepatitis C Virus Infection Treatments to Be Discontinued

Two Hepatitis C Virus Infection Treatments to Be Discontinued

The discontinuation is voluntary and is not related to product quality, safety or efficacy.

HBV Status Linked to Disease Activity and Progression in Rheumatoid Arthritis

HBV Status Linked to Disease Activity and Progression in Rheumatoid Arthritis

Patients with rheumatoid arthritis with chronic hepatitis B virus infection demonstrated greater radiographic progression and poorer clinical response at 1 year.

Hepatitis C-Exposed Infants Not Adequately Screened

Hepatitis C-Exposed Infants Not Adequately Screened

Low screening rate seen at same time as increase in hepatitis C virus prevalence among pregnant women.

Real-Life Renal Outcomes With Sofosbuvir in Chronic Hepatitis C

Real-Life Renal Outcomes With Sofosbuvir in Chronic Hepatitis C

Sofosbuvir-based treatment appears to guarantee renal safety for patients with chronic hepatitis C virus over one year of follow-up.

Methadone Maintenance Therapy Associated With Greater Access to Physician Care in HCV-Positive Drug Users

Methadone Maintenance Therapy Associated With Greater Access to Physician Care in HCV-Positive Drug Users

The investigators suggest that enrollment in a methadone maintenance therapy program may be helpful in providing access to HCV care in people who inject drugs.

HBV Reactivation Examined in Patients Treated With TNF Antagonists

HBV Reactivation Examined in Patients Treated With TNF Antagonists

The authors examined data from 8887 individuals who began TNF antagonist treatment for an autoimmune disease from 2001 through 2010 and were followed through 2012; 52% of these patients were screened for HBV before treatment.

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

Case Report: Nephrotic Syndrome and Chronic HCV in a 72-Year-Old Woman

A 72-year-old Japanese woman with a 40-year history of lupus nephritis presented with leg edema that had lasted for several weeks.

Metabolic Syndrome Associated With Higher ALT Levels in Chronic Hepatitis B

Metabolic Syndrome Associated With Higher ALT Levels in Chronic Hepatitis B

Findings highlight the importance of screening for metabolic syndrome (MS) and the potential for MS to influence alanine aminotransferase and its interpretation in the context of HBV treatment decisions.

CDC: Recommendations on the Use of Heplisav-B Published

CDC: Recommendations on the Use of Heplisav-B Published

The CDC has published ACIP recommendations regarding the use of Heplisav-B.

Maternal Use of TDF Does Not Further Reduce HBV Transmission

Maternal Use of TDF Does Not Further Reduce HBV Transmission

Maternal use of tenofovir disoproxil fumarate does not lower hepatitis B virus transmission rates.

Sign Up for Free e-newsletters